Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer

NCT ID NCT07699952

Not yet recruiting Disease control Sponsor: Yongsheng Wang Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial tests whether combining an EGFR-targeted pill (EGFR-TKI) with an antibody-drug conjugate (trastuzumab rezetecan) can shrink tumors in people with advanced non-small cell lung cancer that has both an EGFR mutation and HER2 alterations. Participants receive the combination as their first cancer treatment. The study measures how many patients respond and monitors safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
EGFR-TKI combined with trastuzumab rezetecan
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced lung cancer that has both EGFR mutations and HER2 alterations.
What could go wrong
This is a small, early-phase trial (35 participants) with no control group, so results may not confirm benefit. Combining two targeted drugs may also increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR ACTIVATING MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR ACTIVATING MUTATION HER2 LUNG CANCER (NSCLC)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.